Interferon‑γ induced PD‑L1 expression and soluble PD‑L1 production in gastric cancer Y Imai, T Chiba, T Kondo, H Kanzaki, K Kanayama, J Ao, R Kojima, ... Oncology Letters 20 (3), 2161-2168, 2020 | 42 | 2020 |
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma T Maeda, H Kanzaki, T Chiba, J Ao, K Kanayama, S Maruta, Y Kusakabe, ... BMC cancer 19, 1-9, 2019 | 40 | 2019 |
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma H Kanzaki, T Chiba, J Ao, K Koroki, K Kanayama, S Maruta, T Maeda, ... Scientific Reports 11 (1), 5303, 2021 | 26 | 2021 |
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma Y Kusakabe, T Chiba, M Oshima, S Koide, O Rizq, K Aoyama, J Ao, ... Scientific reports 11 (1), 21396, 2021 | 21 | 2021 |
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells J Ao, T Chiba, S Shibata, A Kurosugi, N Qiang, Y Ma, M Kan, T Iwanaga, ... Biochemical and Biophysical Research Communications 549, 171-178, 2021 | 20 | 2021 |
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma J Ao, T Chiba, H Kanzaki, K Kanayama, S Shibata, A Kurosugi, T Iwanaga, ... Journal of Cancer 12 (9), 2694, 2021 | 11 | 2021 |
Effect of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma harboring CTNNB1 mutation in early clinical experience K Ogawa, H Kanzaki, T Chiba, J Ao, N Qiang, Y Ma, J Zhang, S Yumita, ... Journal of Cancer 13 (8), 2656, 2022 | 9 | 2022 |
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis T Sakuma, M Nakamura, T Chiba, T Iwanaga, M Kan, R Kojima, J Ao, ... Laboratory Investigation 102 (10), 1150-1157, 2022 | 8 | 2022 |
The RNA-Binding protein ELAVL1 regulates hepatitis B virus replication and growth of hepatocellular carcinoma cells H Kanzaki, T Chiba, T Kaneko, J Ao, M Kan, R Muroyama, S Nakamoto, ... International journal of molecular sciences 23 (14), 7878, 2022 | 8 | 2022 |
Antiviral compounds screening targeting HBx protein of the hepatitis B virus Y Ma, S Nakamoto, J Ao, N Qiang, T Kogure, K Ogawa, M Nakagawa, ... International journal of molecular sciences 23 (19), 12015, 2022 | 7 | 2022 |
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma N Qiang, J Ao, M Nakamura, T Chiba, Y Kusakabe, T Kaneko, A Kurosugi, ... International Immunopharmacology 118, 110068, 2023 | 3 | 2023 |
Successful identification of a novel therapeutic compound for hepatocellular carcinoma through screening of ADAM9 inhibitors K Ogawa, T Chiba, M Nakamura, J Arai, J Zhang, Y Ma, N Qiang, J Ao, ... Anticancer research 43 (3), 1043-1052, 2023 | 3 | 2023 |
Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma R Kojima, S Nakamoto, T Kogure, Y Ma, K Ogawa, T Iwanaga, N Qiang, ... World Journal of Virology 12 (3), 209, 2023 | 2 | 2023 |
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells T Iwanaga, T Chiba, M Nakamura, T Kaneko, J Ao, N Qiang, Y Ma, ... Biochemical and Biophysical Research Communications 642, 192-200, 2023 | 1 | 2023 |
Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis J Ao, N Qiang, H Kanzaki, M Nakamura, R Kakiuchi, J Zhang, R Kojima, ... American Journal of Physiology-Cell Physiology 327 (4), C1150-C1161, 2024 | | 2024 |
S1576 Identification of CD4+ T Cells Expression Profiles Based on Transcriptome Analysis Between Primary Sclerosing Cholangitis and Ulcerative Colitis J Zhang, R Nakagawa, M Ouchi, Y Ohta, K Ogawa, N Qiang, T Kogure, ... Official journal of the American College of Gastroenterology| ACG 118 (10S …, 2023 | | 2023 |